Most Accessed Articles

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

, 2018; 11(3): 200-208.

Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer

DOI: 10.2174/1874471011666180502104524

Mechanisms of Radiation Bystander and Non-Targeted Effects: Implications to Radiation Carcinogenesis and Radiotherapy

, 2018; 11(1): 34-45.

Rasoul Yahyapour, Elahe Motevaseli, Abolhasan Rezaeyan, Hamid Abdollahi, Bagher Farhood, Mohsen Cheki, Masoud Najafi* and Vilmar Villa

DOI: 10.2174/1874471011666171229123130

Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines

, 2018; 11(1): 73-75.

Heinz H. Coenen*, Antony D. Gee*, Michael Adam, Gunnar Antoni, Cathy S. Cutler, Yasuhisa Fujibayashi, Jae Min Jeong, Robert H. Mach, Thomas L. Mindt, Victor W. Pike and Albert D. Windhorst

DOI: 10.2174/187447101101180404111248

Theranostic Applications of Lutetium-177 in Radionuclide Therapy

, 2016; 9(1): 94-101.

Tapas Das and Sharmila Banerjee

DOI: 10.2174/1874471008666150313114644

Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody

, 2016; 9(1): 44-53.

Shankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S. Jhanwar, Gurveen Kaur, Scott T. Tagawa, David M. Nanus, Neil H. Bander and Stanley J. Goldsmith

DOI: 10.2174/1874471008666150313114005

Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT

, 2016; 9(1): 8-18.

Wouter A.P. Breeman, Ho Sze Chan, Rory M.S. de Zanger, Mark K. Konijnenberg and Erik de Blois

DOI: 10.2174/1874471008666150313111131

Webmaster Contact:
Copyright © 2018 Bentham Science